Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MK-4884 tested for safety in advanced cancers

NCT ID NCT07600749

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 9 times

Summary

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors: * Colorectal carcinoma (CRC) * Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features) * Nonsquamous non-small cell lung cancer (NSCLC) * Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC) * Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) * Has adequate organ function * Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable Exclusion Criteria: * Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug * Has a history of clinically significant cardiac, cardiovascular and/or cerebrovascular disease * Has a serious nonhealing wound, ulcer, or bone fracture * Has an active infection(s) requiring systemic therapy * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Known additional malignancy that is progressing or has required active treatment within the past 2 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has a history of stem cell/solid organ transplant * Has not adequately recovered from major surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cancer cholangiocarcinoma colorectal carcinoma gallbladder cancer neoplasm non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    8 sites in 5 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • CHUV (centre hospitalier universitaire vaudois) ( Site 0103)

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

  • Cantonal Hospital St.Gallen ( Site 0101)

    RECRUITING

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0002)

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • NEXT Oncology ( Site 0151)

    RECRUITING

    San Antonio, Texas, 78229, United States

  • National Cancer Center Hospital ( Site 0201)

    RECRUITING

    Chūō, Tokyo, 104-0045, Japan

  • Ospedale Regionale Bellinzona e Valli ( Site 0104)

    RECRUITING

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Rabin Medical Center ( Site 0053)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0051)

    RECRUITING

    Haifa, 3109601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.